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Abstract
Botulinum neurotoxins have a very high affinity and specificity for their target cells requiring two different co-receptors
located on the neuronal cell surface. Different toxin serotypes have different protein receptors; yet, most share a common
ganglioside co-receptor, GT1b. We determined the crystal structure of the botulinum neurotoxin serotype A binding
domain (residues 873–1297) alone and in complex with a GT1b analog at 1.7 A ˚ and 1.6 A ˚, respectively. The ganglioside GT1b
forms several key hydrogen bonds to conserved residues and binds in a shallow groove lined by Tryptophan 1266. GT1b
binding does not induce any large structural changes in the toxin; therefore, it is unlikely that allosteric effects play a major
role in the dual receptor recognition. Together with the previously published structures of botulinum neurotoxin serotype B
in complex with its protein co-receptor, we can now generate a detailed model of botulinum neurotoxin’s interaction with
the neuronal cell surface. The two branches of the GT1b polysaccharide, together with the protein receptor site, impose
strict geometric constraints on the mode of interaction with the membrane surface and strongly support a model where
one end of the 100 A ˚ long translocation domain helix bundle swing into contact with the membrane, initiating the
membrane anchoring event.
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Introduction
Botulism is a neuroparalytic disorder which is caused by
botulinum neurotoxin (BoNT). It has a lethal intravenous dose of
1–5 ng/kg [1,2], and acts by blocking the release of acetylcholine
at the neuromuscular junctions, paralyzing the affected muscles.
Despite its high toxicity, numerous widely used medical applica-
tions of the toxin have emerged in recent years [3,4]. BoNT is a
protease which is produced by Clostridium botulinum as a 150 kDa
protein which must be proteolytically cleaved to become active.
Once the two chains are formed, the light chain (,50 kDa) and
the heavy chain (,100 kDa), continue to be associated through
extensive interactions, including a cysteine bond and the
translocation domain belt [5]. Seven serotypes of BoNT (A–G)
have been identified and isolated. Each serotype has a different
specificity or host organism, with serotype A, B and E (BoNT/A, -
B and -E) as the most common source of infection in humans.
Additionally, the different toxin serotypes are believed to utilize
different protein receptors to enter the target cell.
The holotoxin structures of BoNT/A and B have been solved
[5,6], and both structures contain three well-defined functional
domains. In each, the C-terminal part of the heavy chain, the
binding domain, interacts with specific gangliosides and protein
receptors located on the presynaptic nerve terminals leading to
endocytosis of the neurotoxin (Figure 1). SV2 has been proposed
to be a protein receptor for BoNT/A [7], but it is possible that
other receptors are involved, while Synaptotagmin I and II (Syt-I
and -II) have been identified as protein receptors for BoNT/B and
BoNT/G [8,9,10,11]. Thus far, the only toxin-protein receptor
complex that has been determined is the structure of BoNT/B in
complex with the recognition domain of the Syt-II receptor [8,9].
Gangliosides have been shown to be critical for the toxicity and
binding of BoNT serotypes A, B and G, for which the protein
receptors have also been identified. When ganglioside biosynthesis
is inhibited in neuroblastoma cells, BoNT/A is inactive, likely
because of its inability to penetrate the cells in the absence of
gangliosides [12]. Gangliosides consist of a lipid part (a ceramide)
linked to a complex polysaccharide head group displayed on the
membrane surface. The polysaccharide groups contain sialic acids,
but the number, composition and positions of the monosaccharide
units vary between different gangliosides (Figure 2). GT1b is the
ganglioside with the highest affinity to several of the toxin
serotypes, including BoNT/A and B, and its carbohydrate moiety
is composed of seven monosaccharides (Figure 2). All toxin
serotypes, except D, utilize gangliosides as co-receptors [13,14].
A dual-receptor model has been proposed for the infective
process of BoNT, necessitating binding with both a protein
receptor and a ganglioside co-receptor [11,15] to induce paralysis.
PLoS Pathogens | www.plospathogens.org 1 August 2008 | Volume 4 | Issue 8 | e1000129It has been suggested that the acidic environment of the
endocytotically absorbed vesicle induces a drastic rearrangement
of BoNT, specifically in the N-terminal part of its heavy chain, the
translocation domain. This rearrangement leads to the transloca-
tion of the light chain into the cytosol, possibly through a
transmembrane channel [2]. The extreme potency of the BoNTs
and the high affinity to their targets is the result of the
simultaneous interaction between the toxin and its two co-
receptors on the cell surface (Figure 1).
We have solved the crystal structure of the binding domain of
BoNT/A in complex with the polysaccharide moiety of the
ganglioside GT1b (Figure 3A), the first step in cell recognition.
The toxin interacts with one protein receptor, and also with a
specific ganglioside co-receptor. The first structure of a BoNT
(BoNT/B) in complex with its protein receptor (Synaptotagmin II;
Syt-II) was previously reported [8,9]. Now, we can present the first
structure of a BoNT in complex with its ganglioside co-receptor,
GT1b. By applying the information we have obtained about this
ganglioside interaction, we can generate a picture of the toxin’s
simultaneous interaction with its two co-receptors (Figure 1 and
Figure 4). The final model supports the model, where the long
helixes of the translocation domain enter the cell membrane at a
steep angle [16] Figure 1. We now believe that the high affinity
generated by the interaction with the two co-receptors is simply a
product of the two individual affinities, without any major
contributions from allosteric effects induced by the ganglioside.
We believe that the general features of the ganglioside binding
observed here are representative for all the six ganglioside
interacting BoNT serotypes (i.e. all serotypes except D).
Materials and Methods
GT1b analog synthesis
The GT1b analog was synthesized from the lactose derivative 2-
(trimethylsilyl)ethyl 2,6-di-O-benzyl-b-D-galactopyranosyl-(1R4)-
2,3,6-tri-O-benzyl-b-D-glucopyranoside using the reaction scheme
described by Ishida et al. [17].
Protein expression and purification
The C-terminal heavy chain of BoNT/A1, residues 876–1296,
was cloned into a pET28a His-tag vector (Novagen). For protein
expression, transformed BL21-AI E. coli cells were precultured in LB
medium containing kanamycin (50 mg/ml) at 37uC overnight. The
prepared pre-inoculum wastransferredtotwelve1000 mlculturesof
LB media containing 50 mg/ml kanamycin and incubated at 37uC
untiltheOD at600 nm reached0.6.Proteinexpression wasinduced
with 1 mM isopropyl b-D-1-thiogalactopyranoside (IPTG) and
0.2% arabinose, and the culture was incubated at 37uCf o r4h o u r s .
Cells were resuspended in a lysis buffer containing 50 mM Tris-HCl
pH 8.0, 500 mM NaCl, 10 mM imidazole and EDTA-free protease
inhibitors (Roche) followed by the addition of lysozyme (0.3 mg/ml).
After30 min incubation at roomtemperature, benzonasewasadded
(0.5 U/ml), the cells were incubated 30 min at room temperature
and the cells were sonicated. The crude lysate was clarified by
centrifugation at 100 000gfor45 min at5uC andfiltration througha
0.45 mm membrane. The supernatant was loaded onto a column
packed with Nickel IMAC Sepharose 6 Fast Flow resin (GE
Healthcare) equilibrated with 20 mM Tris-HCl buffer pH 8.0
containing 500 mM NaCl and 10 mM imidazole. Elution was
performed using 500 mM imidazole in the same buffer.
The protein sample was further purified by size-exclusion
chromatography using a Sephacryl S-200 HR column (GE
Healthcare) pre-equilibrated with 10 mM Tris-HCl buffer pH 8.0,
20 mM NaCl, 1 mM EDTA and 0.1% Triton X-100. Pure protein
wasconcentratedusing30 kDacutofffilters(Centricon).Theprotein
concentration was determined by UV-Vis absorbance measure-
ments using an extinction coefficient of 86 250 M
21 cm
21.
Crystallization and structure determination
0.8 ml of the BoNT/A binding domain (15 mg/ml) in a buffer
containing 6 mM GT1b analog, 13 mM Tris pH 8, 18 mM
NaCl, 0.5 mM EDTA, 0.05% Triton-X-100 was mixed with
0.8 ml well solution (21% PEG3350, 0.2 M MgCl2, 0.1 M BisTris
pH 5.5) in a hanging drop experiment at 20uC. The GT1b-
protein solution was preincubated for 30 min prior to setting up
the drops. For the apo structure, the protein concentration was
13 mg/ml, GT1b was omitted and the well solution was 18%
PEG3350, 0.2 M MgCl2, 0.1 M BisTris pH 5.2. The crystals were
flash frozen in liquid nitrogen after the addition of well solution
complemented with 20% glycerol to the crystallization drop.
Diffraction data was collected at 100 K on beamline 11.1 at the
Stanford Synchrotron Radiation Laboratory (SSRL). The data
was processed using the programs XDS and XSCALE [18];
statistics are presented in Table 1. The binding domain from the
BoNT/A holotoxin (PDB: 2NYY) was used as a search model
using MOLREP [19]. wARP [20] was used to build an initial
model that was refined by iterative rounds of model building using
Coot [21] and Refmac5 [22] with 10 TLS groups [23]. The final
model of the GT1b complex includes BoNT/A residues 873–
1297. The apo structure residues 1229 and 1230, and the
CH2CH2Si(Me)3 and Sia7 of the GT1b analog in the complex
were disordered and therefore not modeled. His 873–Asp 875 and
Gln 1297 that are results of the cloning procedure are included in
the final structures. Interestingly the additional C-terminal
glutamine is making extensive crystal contacts; possibly being
important for the formation of the crystal lattice. ProDRG [24]
was used to generate the geometrical restraints for the GT1b
analog. PyMol (www.pymol.org) was used to generate illustrations.
ESPript [25] and SSM [26] was used for the structural alignments.
Coordinates for both structures have been deposited in the Protein
Data Bank. The accession numbers are: BoNT/A binding domain
(2VUA), and BoNT/A binding domain-GT1b complex (2VU9).
Accession numbers
The Protein Data Bank (http://www.rcsb.org/pdb) accession
numbers for the coordinates for the structures of the complexes
presented in this article; apo BoNT/A binding domain (2VUA),
and BoNT/A binding domain-GT1b complex (2VU9). The
Protein Data Bank accession numbers for the additional structures
discussed in this paper are; BoNT/A holotoxin, 3BTA; BoNT/A
Author Summary
Botulinum neurotoxins are the most toxic substances
known and are classified as a category A bioterrorism
agent. Ongoing work on the development of countermea-
sures for the neurotoxin has been limited by an
incomplete understanding of the means by which the
toxin enters the cell. Our study provides a detailed look at
how the toxin binds its ganglioside co-receptor on the cell
surface. Together with earlier work this generates a
detailed description of how the toxin binds its two co-
receptors to position it for entrance into the neuronal cell.
This structural data provides critical new insight about the
action of the botulinum neurotoxins that can be applied
toward the development of agents to block toxin uptake
in the digestive system and/or inhibit the binding of the
toxin at the neuromuscular junction.
The Neurotoxin GT1b Complex
PLoS Pathogens | www.plospathogens.org 2 August 2008 | Volume 4 | Issue 8 | e1000129Figure 1. A model of the process of botulinum neurotoxin binding to the neuron surface. GT1b has been modeled into the BoNT/B Syt-II
complex (2NP0) based on the BoNT/A binding domain-GT1b complex. Toxin displayed as rainbow colored ribbon, GT1b as CPK spheres and Syt-II as a
gray ribbon. A: free toxin above the cell surface displaying GT1b. B: Toxin bound to GT1b on the cell surface. C: Toxin bound to GT1b and Syt-II on the
neuron surface. D: Toxin entering the cell through endocytosis. E: Side view of the toxin along the axis of possible rotation. F: The N-terminal domain
of the translocation domain (loops 590 and 750 in BoNT/B and loops 600 and 760 in BoNT/A) of the 100 A ˚ long helixes from the translocation domain
swinging into contact with the membrane inside the acidified endosome; it is also possible that the other end of the translocation domain make the
initial contact with the membrane.
doi:10.1371/journal.ppat.1000129.g001
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PLoS Pathogens | www.plospathogens.org 3 August 2008 | Volume 4 | Issue 8 | e1000129Figure 2. Gangliosides, GT1b and its interactions with BoNT/A. A: GT1b, GD1a and GM1 shown in decreasing order of affinity towards BoNT/
A; also GD1b and GQ1b are shown. B: In GT1b a ceramide is present at the R position. In the GT1b analog used here; a CH2CH2Si(Me)3 group replaces
the ceramide. C: Schematic picture of GT1b and its hydrogen bonds to BoNT/A. The hydrogen bonds between the protein (blue) and GT1b (black) are
shown as dotted red lines and the GT1b internal hydrogen bonds as dotted black lines. Distances of key hydrogen bonds are displayed in A ˚. Sia7 that
is disorderd in the complex is shaded gray. Numbered monosaccharide names are shown; Glc=glucose; Gal=Galactose; GalNAc=N-
acetylgalactosamine; Sia=sialic acid. D: sA weighted Fo-Fc omit map of the GT1b analog contoured at 2.3 s; oriented approximately as in C.
doi:10.1371/journal.ppat.1000129.g002
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PLoS Pathogens | www.plospathogens.org 4 August 2008 | Volume 4 | Issue 8 | e1000129holotoxin (2.6 A ˚), 2NYY; BoNT/B holotoxin, 1EPW; BoNT/B
with trisaccharide, 1F31; BoNT/B with Syt-II, 2NP0 and 2NM1;
BoNT/B binding domain, 1Z0H; TeNT binding domain with
ganglioside, 1FV2; Siglec-7 with GT1b, 2HRL and Cholera toxin
with GM1, 2CHB. Swiss-Prot accession numbers; BoNT/D,
P19321 and BoNT/G, Q60393.
Results
Here, we report the crystal structure of the BoNT/A binding
domain to 1.7 A ˚, and its complex with the polysaccharide moiety
of GT1b to 1.6 A ˚. Three BoNT/A holotoxin structures have been
reported previously [5,27]; the highest resolution structure was
that of the BoNT/A holotoxin complexed with a monoclonal
antibody to 2.6 A ˚ [27]. The BoNT/A binding domain has two sub
domains that each consist mainly of b–sheets (Figure 3A). The N-
terminal half has an all b-sheet, jelly roll barrel fold, while the C-
terminal half has a b-trefoil fold. Clear density is observed for the
key shallow grove binding pocket anchored by Trp 1266.
GT1b–BoNT/A binding domain complex
In total, eight BoNT residues make hydrogen bonds to the
GT1b polysaccharide, five of the hydrogen bonds are to Gal4 and
GalNAc3 (Figure 2C) that also have the lowest B values of the
GT1b monosaccharides. Because of reports of a slow conforma-
tional change being induced in BoNT/A by GT1b binding [28],
we pre-incubated the protein with the GT1b analog at pH 8 in a
low ionic strength buffer for approximately 30 min prior to setting
up crystallization trials. The GT1b complex crystals grew at
pH 5.5 which is comparable to the pH inside the endosome; this
indicates that the neurotoxin ganglioside complex could be stable
also inside the endosome. Six of the seven monosaccharides in the
GT1b analog are clearly defined by the electron density, while
Sia7 is disordered (Figure 2D). The ganglioside GD1a is
distinguished from GT1b only by the absence of the Sia7 moiety,
yet GD1a still displays high affinity for the toxin [28]. The GT1b
analog used here differs from GT1b only in the replacement of the
ceramide (the lipid), that would be buried inside the membrane,
for a 2-(trimethylsilyl)ethyl group (Figure 2B).
Trp 1266 is conserved among the BoNT serotypes, and on
BoNT/A is located in a binding groove that makes extensive
interactions with GT1b. Gal4 and GalNAc3 interact with Trp
1266 through hydrophobic stacking (Figure 2C and Figure 5).
Additionally, the indole nitrogen of Trp 1266 hydrogen bonds
with the carboxylic acid group of Sia6 (3.1 A ˚); further underlining
the importance of Trp 1266 in ganglioside binding (Figure 2C).
Tyr 1267 is also conserved in all ganglioside binding BoNT
serotypes [29], and extends the hydrophobic part of the binding
pocket generated by Trp 1266 (Figure 2C and Figure 5).
Figure 3. Binding domain of BoNT/A in complex with GT1b and comparison with the Apo structure. A: Overall ribbon representation of
the BoNT/A binding domain in rainbow color representation, from the N-terminus (blue) to the C-terminus (red). The GT1b polysaccharide as yellow
sticks. B: Comparison of the Apo structure (blue ribbons) and the GT1b complex (yellow ribbons). The GT1b polysaccharide is shown as yellow sticks.
The position of the 1228–1234 loop is indicated by an arrow.
doi:10.1371/journal.ppat.1000129.g003
Figure 4. BoNT/B bound to Syt-II with the overlaid GT1b
modeled from the BoNT/A binding domain complex. BoNT/B as
red ribbon; Syt-II in grey ribbon and GT1b represented as CPK spheres.
doi:10.1371/journal.ppat.1000129.g004
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PLoS Pathogens | www.plospathogens.org 5 August 2008 | Volume 4 | Issue 8 | e1000129The interactions between GT1b and the toxin are shown in
Figure 2C and a table describing the interactions is available as
Table S1. In addition, some of the most important interactions are
described here. Ser 1264 (2.7 A ˚) and His 1253 (2.8 A ˚) hydrogen
bonds to Gal4, both of these residues are highly conserved
between the different serotypes and also to the TeNT. Glu 1203
hydrogen bonds to both Gal4 (2.7 A ˚) and GalNAc3 (2.6 A ˚) and the
carbonyl oxygen of Phe 1252 coordinate Gal4 (2.6 A ˚) (Figure 2C).
There are also two internal hydrogen bonds within GT1b.
The importance of several of the residues in BoNT/A involved in
GT1b binding has previously been identified by mutational studies
[29]. All mutants that lower the affinity to GT1b are targeting
residues that makedirect interactionswith the GT1b inthecomplex.
Importantly, mutants of Trp 1266 and Tyr 1267 fail to bind GT1b;
in fact, even the removal of a single oxygen atom from the binding
site, as in the Y1267F mutant, leads to a dramatically lower affinity
for GT1b [29]. The two hydrogen bonds formed by the hydroxyl
group of Tyr 1267 to the backbone of Phe 1252 are likely to be
important for the correct positioning of tyrosine and the structural
integrity of the binding site. Other residues where the interaction is
dramatically affected by mutation (His 1253, Glu 1203, Ser 1264)
are making crucial hydrogen bonds to GT1b [29].
Four water molecules mediate hydrogen bonds between BoNT/
A and GT1b; additionally, three water molecules mediate internal
hydrogen bonds within GT1b; these are all listed in Table S1. All
of these water molecules are likely to be important for the binding
of GT1b to the toxin. Two of the water molecules that are
mediating hydrogen bonds between GT1b and the protein (3376
and 3350) have counterparts located in the same positions in the
Apo structure; interestingly water 3350 also has a counterpart in
the BoNT/B structures [6,8,9]. This emphasizes the fact that the
ganglioside binding site is preset for binding and few structural
changes are necessary for optimal binding to gangliosides.
Apo BoNT/A binding domain structure
We have also solved the structure of the BoNT/A binding
domain in the absence of ganglioside. Circular dichroism (CD)
measurements on BoNT/A have indicated that there are large
conformational changes induced by GT1b binding, leading to an
increase in the helical contents and a decrease to less than half of
the b-sheet contents [28]. The GT1b complex structure and the
apo structure reported here are very similar with an overall rmsd
of 0.3 A ˚ (Figure 3B). It is possible that BoNT/A holotoxin become
partially inserted into the low dielectric environment of the GT1b
micelles. This insertion would dramatically influence the CD
spectra. The GT1b analog complex reported here represents the
toxin bound to the presynaptic membrane before the translocation
process is initiated.
Some structural differences are observed between the GT1b
complex and the apo structure. The side chain of Arg 1276 has
moved 1 A ˚ closer to the position of Sia6 and the side chain of Trp
1266 has rotated 9 degrees, moving it closer to the hydrophobic
face of Gal4. But most of the amino acids directly interacting with
GT1b have similar conformations in the two structures. The
exception is Tyr 1117, which directly coordinates GT1b. Tyr 1117
has rotated 25 degrees around the C-beta C-gamma bond upon
the binding of GT1b; in addition to this rotation the hydroxyl
group of Tyr 1117 has moved 1.2 A ˚ to a position where it can







Space group C2221 C2221
Unit cell (a,b,c in A ˚) 73.0, 114.5, 105.8 72.7, 116.1, 105.5
Resolution (A ˚) 20-1.7 (1.8-1.7) 20-1.6 (1.7-1.6)
Rsym (%) 4.0 (53.1) 4.2 (40.5)
,I/sI. 27.0 (4.2) 27.1 (5.3)
Completeness (%) 99.0 (98.4) 99.6 (99.2)
Redundancy 7.8 (7.5) 7.4 (7.3)
Rcryst (%) 17.0 16.2
Rfree (%) 20.5 18.6
r.m.s. deviation bond length (A ˚) 0.014 0.012
r.m.s. deviation bond angle (u) 1.5 1.5





Most favored (%) 87.4 88.2
Additional allowed (%) 12.1 11.3
Generously allowed (%) 0.3 0.3
Disallowed (%)* 0.3 0.3
*Two ramachandran plot outliers Asn 1025 and Asn 1127 are clearly defined by
the electron density, Asn1127 is involved in a strong crystal packing
interaction.
doi:10.1371/journal.ppat.1000129.t001
Figure 5. Close-up of the GT1b binding site. GT1b represented as
sticks with yellow carbons. The GT1b coordinating residues are shown
as sticks with grey carbons.
doi:10.1371/journal.ppat.1000129.g005
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area of interaction, one region of the protein that has major
differences between the GT1b complex and the Apo structure is
the 1228–1234 loop which has adopted an alternative conforma-
tion. The C-alpha of residue 1231 has moved as much as 8 A ˚, and
residues 1229 and 1230 of this loop are disordered in the Apo
structure but clearly visible in the GT1b complex (Figure 3B). The
distance between GT1b and the 1228–1234 loop is approximately
15 A ˚, while the side chains of Leu 1116, sitting next to Tyr 1117,
and Ile 1231 located on the 1228–1234 loop are 4 A ˚ apart. There
is a slight shift in the positions of Leu 1116 and Tyr 1117 between
the structures which opens for the possibility that the conforma-
tional change of the 1228–1234 loop is induced by GT1b binding;
but it is more likely that this change is instead induced by a small
shift in the crystal packing.
Comparison of BoNT/A holotoxin and binding domain
structure
The 1230 loop region in the holotoxin structure (residues 1226–
1236) [5,27] points away from binding domain relative to the apo
structure, specifically Gly 1230 that moves 12 A ˚. In addition,
residues 1271–1277 have also reoriented when comparing the
BoNT/A holotoxin structure. Ser 1275 and Arg 1276 that
coordinate Sia5 in the GT1b complex are located within this
section. However, the positions of residues 1271–1277 are nearly
identical when comparing the GT1b complex and apo binding
domain structure presented here. Given the location of this region
and how the molecules pack in the crystal lattice when comparing
the holotoxin structure and the binding domain, it is possible that
these changes are caused by the differences in crystal packing.
Another segment of the binding domain facing the translocation
domain in the holotoxin structure (928–939) has adopted an
alternative conformation with C-alpha positions moving by up to
10A ˚.Thisislikelytobetheresultoftheexposureofthehydrophobic
translocationdomain interactionareatosolvent.A rearrangement of
approximately the same section of the binding domain of BoNT/B
has been reported when the binding domain is detached from the
rest of the toxin [30]; this segment in the BoNT/A and BoNT/B
binding domains have different orientations. The regions where
changes have occurred in BoNT/A are highlighted in the structure
based sequence alignment available as Figure S1.
Discussion
BoNT/A and BoNT/B have a single ganglioside binding site
[29], Trp 1266 of BoNT/A and residues in its proximity have
been shown by several investigators to be critical for ganglioside
binding; mutations of residues in this region abolish ganglioside
binding [29]. Ganglioside binding quenches the tryptophan
fluorescence of BoNT/A and the only solvent exposed tryptophan
in BoNT/A is Trp 1266 [31,32]. Even though many reports have
highlighted the importance of gangliosides and the Trp 1266
binding region, the details of the interactions have been elusive.
Studies of trypsin digested BoNT/A have indicated that the last 30
amino acids of the toxin are important for toxicity [33]. Structural
data on the binding of sialyllactose to BoNT/B [6] have indicated
that there could be large differences in ganglioside binding
between the TeNT [34] and the BoNTs. Also, it has recently been
suggested that the Syt-II binding site in BoNT/B would be in
direct contact with the Sia5 moiety of GT1b [8]; this would place
Sia5 approximately 20 A ˚ from the Sia5 position observed in the
Hc/A-GT1b complex presented here.
Generally, the ganglioside is believed to bind the toxin without
inducing any large conformational changes, much as in the lock
and key model (Figure 3B); but there have been several suggestions
in the literature that gangliosides change the affinity between the
toxin and its protein receptor; either by inducing conformational
changes and/or by direct interactions. GT1b binds to all serotypes
of BoNT that have been shown to interact with gangliosides, but
the ganglioside specificity varies between serotypes. GT1b is the
ganglioside with highest affinity for serotype A and B. Serotypes A,
B, C, E and F all bind GT1b and GD1a. Serotype A, B, C and F
also bind GD1b (Figure 2A). The ganglioside GQ1b can bind
serotype A and E [13]. Serotype D has been reported not to bind
or interact with gangliosides, but instead BoNT/D interacts with
phosphatidylethanolamine [14]. Serotype G interacts with gangli-
osides but the specificity is unclear [11,35]. While most BoNTs
have been shown to interact with gangliosides, the specificities
above should be interpreted cautiously; since all serotypes have not
been tested with all the different gangliosides.
We now suggest that the toxins interactions with its receptors are
not as complex as previously believed. Only the simultaneous
interactions with two receptors are necessary to obtain the high
avidity by the ‘‘dual receptor’’ model. The existence of a major
communication between these two binding sites might be a more
complex mechanism than needed to explain the interaction. The
polysaccharide head group of GT1b is dynamic, and we have now
shown that the ganglioside binding site of BoNT/A is rigid with very
limited structural changes being induced upon binding. Binding to a
static binding site is not a general mechanism for ganglioside
interactions since conformational changes are induced by the
binding of GT1b to the Siglec-7 receptor. Siglec-7 is involved in
signaling in the immune and nervous systems [36], where specificity
and control are likely to be important factors for binding. There are
some similarities in the GT1b interactions between Siglec-7 and
BoNT/A; they both have shallow binding pockets with tryptophans
involved in hydrophobic stacking interactions. The structure of
cholera toxin in complex with the ganglioside GM1 also reveals
similarities [37], a shallow binding groove binds the ganglioside and
a key tryptophan makes hydrophobic interactions. In all of these
complexesthe gangliosidesarepositionedbyseveralhydrogen bonds
in addition to tryptophan interactions. The tryptophan interaction
appears to be a common hallmark of the interactions between
gangliosides and proteins.
Comparison between the TeNT GT1b analog complex
[34] and the BoNT/A GT1b analog complex
We can now show that BoNT/A binds to gangliosides in the
same binding site and in a similar manner to TeNT (Figure 6),
though there are some large differences in the interaction. Gal4
and GalNac3 are bound in a similar manner and make key
interactions with, conserved or semi-conserved residues. The Sia5
group is critical for the affinity of BoNT/A to gangliosides, since
the affinity to GD1a is much higher than that of GM1 [28]. The
TeNT has a high affinity for GT1b and GQ1b, but also for GD1b
[38,39], which is GT1b without the Sia5 unit (Figure 2A). There is
approximately 2 A ˚ difference between the positions of the Sia5
group in the TeNT complex and the BoNT/A complex structures
(Figure 6). Tyr 1117 and Phe 1252 in BoNT/A make hydrophobic
interactions with Sia5, and the presence of these two bulky
residues leads to a more closed Sia5 binding site in BoNT/A
versus TeNT complex structure where these interactions among
the comparable residues Ala 1134 and Thr 1270 are absent
(Figure 6). Interestingly, Ser 1275 of BoNT/A, which makes a
bond to Sia5, is not conserved.
Gal4 and GalNAc3 are coordinated by Glu 1203 in the BoNT/
A complex; in the TeNT complex structure Asp 1222 is present in
this position [34]. The carboxyl group of Asp 1222 in the TeNT
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positions on Gal4 and GalNAc3 as Glu 1203 in the BoNT/A
complex (Figure 2C). Glu 1203 is conserved among all ganglioside
binding BoNT serotypes except serotype G where it is replaced by
a glutamine [29], which could be able to coordinate the
ganglioside in a similar way. TeNT has an additional ganglioside
binding site which corresponds to the region around Arg 1131 in
BoNT/A [34,40]; but this area of BoNT/A has large structural
differences from TeNT and does not participate in ganglioside
binding in BoNT/A. This is in agreement with the finding that
BoNT/A and BoNT/B have a single ganglioside binding site [29].
GT1b in the BoNT/A complex does makes two interactions with
a crystallographically related molecule; Glu 969 and Asn 970
interact with Sia6; although, these residues are not conserved and
the interaction is unlikely to have any biological significance.
Another difference between the TeNT ganglioside complex and
the BoNT/A GT1b analog complex includes the orientation of the
disialic arm (Sia6) which is very different between the two
structures, and the Glc1–Gal2 saccharides are in a different
position (Figure 6). This is not surprising since the disialic arm
(Sia6) is located in a different position and there are no interactions
between the Glc1–Gal2 saccharides and the protein. A non
natural b-anomer of Sia6 is present in the GT1b analog used in
the TeNT complex [34], while we use the natural a-anomer. This
difference changes the relative positions of the Sia6 ring and the
Sia6 carboxylic acid group. Trp 1266 in the BoNT/A structure
coordinates the carboxylic acid group of Sia6, the corresponding
residue in TeNT is Trp 1289 (Figure 6). It is unclear how GT1b
would interact with the second GT1b binding site of TeNT and
Trp 1289 if the a-anomer of GT1b were used. It is likely that the
general features of the TeNT GT1b binding would be unaltered,
but that the position and interactions of the Sia6 and its carboxylic
acid group with the protein would change.
Co-receptor binding to serotype B
With the structure of the complex between BoNT/B and its
protein receptor Syt-II that has been published [8,9], we can now
combine our structural data of BoNT/A with its ganglioside co-
receptor to produce a model of the ‘‘double receptor’’ interaction
proposed by Montecucco et al. [15]. Additionally, we can observe
that GT1b in our complex with BoNT/A binds to the same
binding pocket as the trisaccharide sialyllactose in the complex
with BoNT/B that has also has been determined [6]. However,
there are very large differences in binding. The Sia unit of
sialyllactose in the BoNT/B complex is rotated by 180 degrees
compared with the Sia5 of the BoNT/A GT1b complex and
located approximately where Gal4 is located in the BoNT/A
GT1b structure. The trisaccharide sialyllactose is only a partial
mimic of a ganglioside, and would be unable to make the key
interactions we observe in the GT1b complex. We believe that the
sialyllactose complex has correctly identified the ganglioside
binding pocket of BoNT/B, but that the binding of a ganglioside
to BoNT/B would be similar to the binding of GT1b to BoNT/A.
The key residues in coordinating the GalNAc3–Gal4 part of
GT1b are all conserved between the BoNT/A and BoNT/B. Trp
1266, Glu1203, His 1253, Ser 1264 in BoNT/A correspond to
Trp 1261, His 1240, Glu 1189 and Ser 1259 in BoNT/B. Phe
1252 in BoNT/A is not conserved in BoNT/B, but the position of
the carbonyl oxygen coordinating GT1b is similar. The main
differences are in the coordination of Sia5; Tyr 1117, Phe 1252
and Ser 1275 that interact with Sia5 in our BoNT/A complex are
not conserved in BoNT/B. The Sia5 of GT1b has been reported
to be important for the interaction between Syt-I and BoNT/B.
This could be the result of the simultaneous binding to
gangliosides and Syt constructs present in the same micelles rather
than a direct interaction between the co-receptors [11]. Our
studies on BoNT/A cannot completely rule out conformational
changes in BoNT/B induced by ganglioside binding leading to an
increased affinity for Syt-I.
The residues that are important for GT1b binding in BoNT/A
have also been mutated in BoNT/B; and the results are very
similar for both serotypes [29]. Since the binding of the GalNAc3–
Gal4 part of GT1b is similar between TeNT complex and our
complex and the key residues in coordinating GalNAc3–Gal4 are
conserved between BoNT/A and B. We believe that GT1b
binding to BoNT/B will be similar to the binding to BoNT/A.
Furthermore, it is likely that the ganglioside binding of BoNT/A is
representative of all ganglioside interacting BoNT serotypes. The
conserved residues corresponding to Trp 1266, Tyr 1267 and Gly
1290 in BoNT/A have been mutated in BoNT/C and are also
important for ganglioside binding in serotype C [41]. These
residues are all part of the ganglioside binding pocket of the
BoNT/A GT1b complex presented here.
Implications for the ‘‘double receptor’’ model
In the GT1b polysaccharide complex presented here, the
distance between the position where the ceramide of GT1b would
Figure 6. A comparison of a GT1b b-anomer (gray sticks) bound
to the TeNT (gray ribbon), and GT1b (yellow sticks) bound to
the BoNT/A binding domain (yellow ribbon). The BoNT/A binding
domain residues Trp 1266 and His 1253 and corresponding TeNT
residues Trp 1289 and His 1271 are shown as sticks.
doi:10.1371/journal.ppat.1000129.g006
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approximate value of the spacing between BoNT/A and the
presynaptic membrane, and puts some restrictions on the toxins
interactions with the different protein receptors of the BoNT
serotypes. The binding site on the toxin has to be able to access the
epitope on the protein receptor while being attached to the
presynaptic membrane by the ganglioside. This holds true for a
modeled ternary complex of BoNT/B, where these distances are
in perfect agreement. It is very likely the initial contact between
the toxin and the neuronal membrane is mediated by GT1b; this
increases the local toxin concentration at the membrane surface
dramatically and gives the toxin the opportunity to diffuse in the
plane of the membrane and bind its protein receptor. When GT1b
is modeled into the Syt-II complex of BoNT/B [8], based on its
binding to the BoNT/A binding domain, the two points of
attachment to the presynaptic membrane are 22 A ˚ apart (Figure 4).
This model gives us the most detailed view yet on the nature of the
‘‘double receptor’’ model of a BoNT. In this model, BoNT/B can
rotate around the axis formed by the two tethers to the membrane,
but this model puts rather strict restraints on the binding,
elucidating a well-defined view of the interaction (Figure 1 and
Figure 4). We now have structural data for several of the stages of
the toxins binding to the neuronal surface; this is presented in
Figure 1. There is a long extended loop (the 1250 loop) pointing
out from BoNT/B located between the Syt-II binding site and the
ganglioside binding site (Figure 4). This loop has a very
hydrophobic tip, consisting of Gly 1246, Ile 1247, Val 1248 and
Phe 1249. These residues are completely exposed on the surface,
and it is possible that they play a part in BoNT/B binding to the
membrane. The axis of possible rotation is perpendicular to the 100
A ˚ long helixes of the translocation domain (Figure 1 and Figure 4).
The rotation around this two-point attachment hinge makes it
possible for one end of the long helix bundle of the translocation
domain to directly interact with the membrane, supporting a
translocation domain insertion model previously suggested [8,16].
The N-terminal (loops 600 and 760 in BoNT/A and 590 and 750 in
BoNT/B) end of the translocation domain has better sterical access
to the membrane surface and is closer to the cluster of negative
charges and the histidines that have been suggested as key residues
for the insertion of the translocation domain into the membrane; but
additional experiments are necessary to clarify which end of the
translocation domain makes the initial contact with the membrane
[32]. The model presented here gives us a glimpse at the initiation of
toxin translocation (Figure 1 and Figure 4).
The interaction of BoNT/A and gangliosides, including GT1b,
is critical for the toxins passage over the digestive epithelial barrier
[42]. Additionally, it is likely that SV2, or an as yet unidentified
receptor, together with gangliosides is necessary for absorption
[42]. In a recent study, the non-toxic neurotoxin-associated
proteins (NAPs) did not influence the toxins passage over the
epithelial barrier; similar results were obtained with toxin alone
and with the toxin-NAP complex [42]. The role of the NAPs is
under debate, but it is possible that their major function is to
protect the toxin from proteases and the acidic environment of the
stomach and not in absorbance. In a competition experiment,
where the toxin was pre incubated with GT1b, a large decrease in
the absorption of the toxin was observed [42]. This would suggest
that the GT1b binding site of the neurotoxin itself is responsible
for the interaction with the epithelial cells and the absorption of
the toxin, and not the NAPs as previously thought. These results
further highlight the important role of the neurotoxin’s GT1b
binding site. Inhibitors targeting GT1b binding could disrupt both
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